The first day she woke up pain free
Jubilant Moment #5
In October 2019, we announced that our Radiopharmacies Division signed an exclusive distribution agreement with Q BioMed for Strontium-89 Chloride (Sr-89), a product indicated for the relief of bone pain in patients with painful skeletal metastases. Jubilant Moment #5 was the day we distributed the first dose of Sr-89 to a patient who relies on us.
Our vision is to Improve Lives Through Nuclear Medicine, it is the cornerstone of everything we do and shipping this does and helping this patient, is why we do what we do. Bone metastases, often cause deep and endless pain. Palliative options for the control of this pain include analgesic support, cytotoxic chemotherapy and external-beam radiotherapy. Sr-89 is used to help provide the patient with relief from the bone pain.
The radioactive strontium is taken up in the bone cancer area and emits beta radiation directly into the metastases with little or no side-effects as compared to other palliative treatment options. In clinical trials, 75% of the cancer patients with metastatic bone disease who received Sr-89 experienced a reduction in pain, with 25%-30% of patients reporting complete pain relief. The impact on the quality of life for patients is immeasurable.